European Central Bank board member warns: The Middle East energy shock has not yet affected wages, and the longer the conflict lasts, the greater the risks become.
European Central Bank member Rehn stated that the energy shock in the Middle East has not yet affected prices and wages, but the longer the conflict lasts, the greater the risk of transmission; the central bank has already raised interest rates twice, and rates may be raised again.
According to Golden Ten Data APP, Olli Rehn, a member of the Governing Council of the European Central Bank, stated that the Middle East energy shock has so far not spread to other prices or wage sectors, but the possibility of such impacts cannot be ruled out.
The Governor of the Bank of Finland said on Tuesday in Helsinki, "Such impacts may gradually and imperceptibly emerge," emphasizing the need to remain vigilant. "The longer the Middle East conflict continues, the greater the risk that rising energy prices will spread more broadly."
Since the outbreak of war, the European Central Bank has raised borrowing costs twice, most recently in September, as the energy shock pushed inflation far above its 2% target. According to sources who spoke to the media last month, officials expect interest rates to be increased further, but any move will depend on upcoming data.
Rehn said that the euro area economy has remained resilient, although growth is still sluggish. Strong demand has made it easier for companies to pass higher costs on to consumers, thereby increasing the risk that the energy shock will transmit more broadly to inflation.
Meanwhile, the Bank of Finland pointed out that as the artificial intelligence (AI) investment boom drives up capital demand, long-term interest rates are also rising. Inflation expectations, mounting public debt, and greater global uncertainty are also fueling this trend.
Rehn stated, "The rise in long-term interest rates is dragging down economic growth and, in turn, curbing the transmission of rising energy prices to other prices and wages."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Bank of England's most hawkish official: The labor market is "stationary" rather than loose, and inflation is deeply entrenched.
The Bank of England hawkish official Mann stated that the labor market is "static" rather than loose, and warned that inflation is deeply entrenched; rising fuel and energy prices may cause inflation to "significantly exceed 4%" early next year.
BUZZ - Bank of America gives Diodes a "Buy" rating, driving its stock price up
October 6 - Semiconductor product manufacturer Diodes (DIOD.O) saw its stock price rise 3.38% in pre-market trading to $107.64. BofA has initiated coverage of DIOD with a “Buy” rating and a price target of $135, implying about 30% upside from the previous closing price. According to the report, DIOD holds a favorable position in the automotive, industrial, and AI data center semiconductor markets, positioning it to expand its market share. The increasing use of semiconductors in automobiles and growing demand for AI infrastructure are expected to drive the company’s long-term growth. The firm anticipates that DIOD’s AI data center business—which currently accounts for about 12% of total revenue—could triple by 2030. As of the previous trading day’s close, the stock’s year-to-date growth has already more than doubled. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translations may contain errors or lack context and are provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.)
BUZZ-BridgeBio shares rise as FDA initiates priority review for dwarfism drug
On October 6th, shares of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% in pre-market trading to $67.80. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the investigational oral drug infigratinib for the treatment of children with achondroplasia, the most common type of dwarfism. The FDA has set a target decision date of February 4, 2027. The application is based on a late-stage clinical trial that met both primary and key secondary endpoints; children treated with infigratinib experienced an adjusted annual growth velocity 1.74 centimeters greater than those given placebo. The drug also improved arm span and body proportions in children under eight years old. No serious adverse events or discontinuations related to the drug were reported. BridgeBio plans to apply for European approval in the fourth quarter of 2026. As of the close of the previous trading day, BBIO shares are down 13.5% year-to-date. (For the convenience of non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation, which is provided for readers’ convenience only. Reuters accepts no liability for any damages or losses arising from the use of automated translation.)
Google (GOOGL.US) spends $4.3 billions on electricity, securing 3,590 megawatts of long-term energy from Constellation Energy (CEG.US).
Google has signed a 3,590 MW power purchase agreement with Constellation Energy, with a quarter of the electricity coming from nuclear power, involving an investment of $4.3 billion.
Crypto prices
More
